Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
In patients treated up to 36 months, amyloid plaque levels continued to decrease in a dose- and time-dependent manner, with levels in the 10 mg/kg fixed-dose group reaching and remaining below a quantitative cut-point discriminating a positive/negative scan. 1 Reduced amyloid plaque levels were also observed in patients switched from placebo to aducanumab during the LTE.
-
50/100
The restricted use of BDZRs may contribute to dementia prevention in the elderly.
-
Continued treatment with lithium was associated with a reduced rate of dementia in patients with bipolar disorder in contrast to continued treatment with anticonvulsants, antidepressants, or antipsychotics.
-
Bipolar disorder is associated with increased risk for dementia.
-
AChEI therapy had a significant effect on the percentage of stage 1 (p = 0.01) and stage 2 (p = 0.03) sleep.
-
This controlled study showed significant short-term efficacy of carbamazepine for agitation with generally good safety and tolerability.
-
In a 6-month, double-blind, placebo-controlled study, 100 to 150 mg/d indomethacin appeared to protect mild to moderately impaired Alzheimer's disease patients from the degree of cognitive decline exhibited by a well-matched, placebo-treated group.
-
Alzheimer's disease (AD) is a progressive neurodegenerative disorder marked by cognitive decline and functional impairment, primarily driven by the accumulation of amyloid-beta (Aβ) plaques and tau tangles.
-
This case suggests that mirtazapine may be beneficial in mitigating GLP-1 RA-induced gastrointestinal side effects, thereby improving adherence and therapeutic efficacy.
-
Donepezil is a central-acting acetylcholinesterase inhibitor aimed at increasing acetylcholine availability at the neuron synapses to enhance cholinergic transmission.
-
With the advent of the first disease-modifying, anti-amyloid β-directed passive immunotherapy for Alzheimer's disease, questions arise who, when, and how to treat.
-
The emergence of the United States Food and Drug Administration (FDA)-approved amyloid-targeting therapies for Alzheimer's disease challenges clinicians and healthcare providers with a transformative landscape.
-
This QSP platform could support clinical practice challenges to optimize real-world treatment paradigms for new and existing amyloid drugs.
-
The US Food and Drug Administration (FDA)'s recent accelerated approval of two anti-amyloid antibodies for treatment of Alzheimer's disease (AD), aducanumab and lecanemab, has caused substantial debate.
-
This cross-sectional study examines upper bound and lower bound annualized Medicare costs for administering aducanumab to beneficiaries with the approved indications of mild cognitive impairment or mild dementia.
-
PET amyloid levels were consistent with sparse-to-no neuritic amyloid-β plaques in 51% of patients after 2 years of therapy.
-
Nearly 30% of adults 40 years and older in the United States are on a statin.
-
Agitation is common and distressing in patients with Alzheimer-type dementia, but safe, effective treatments remain elusive.
-
N/A. ENGAGE and EMERGE are Phase 3 clinical trials designed to confirm the clinical efficacy and safety profile of aducanumab in individuals with Early AD.
-
The predefined superiority of donepezil to the placebo was not confirmed in either active group in the primary analysis.
-
STOPP criteria PIMs, unlike Beers criteria PIMs, are significantly associated with avoidable ADEs in older people that cause or contribute to urgent hospitalization.
-
In relation to placebo, the last observation in phase 1 showed greater improvement with olanzapine or risperidone on the Neuropsychiatric Inventory total score, risperidone on the Clinical Global Impression of Changes, olanzapine and risperidone on the Brief Psychiatric Rating Scale (BPRS) hostile suspiciousness factor, and risperidone on the BPRS psychosis factor.
-
The incidence of hip fracture appears to be associated with benzodiazepine use.
-
To address this, we first examined the prevalence of type 2 diabetes in a community-based controlled study, the Mayo Clinic Alzheimer Disease Patient Registry (ADPR), which follows patients with Alzheimer disease versus control subjects without Alzheimer disease.
-
Community-based, commercially insured, older adults with probable dementia are more likely to take anticholinergics than matched controls.
From across this topic
10 of the 902 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Case Report: SIADH-Induced Hyponatremia Following Sertraline and Quetiapine Use in an Elderly Patient with Dementia: A Case Report
- Repurposing Proteostasis-Modifying Drugs to Prevent or Treat Age-Related Dementia: A Systematic Review
- Current and future treatments for Alzheimer's disease
- Pharmacokinetic evaluation of donanemab for the treatment of Alzheimer's
- Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer's disease
- Inclusion/exclusion criteria in late life depression antidepressant efficacy trials
- New acetylcholinesterase inhibitors for Alzheimer's disease
- Diagnosis and Treatment of Parkinson Disease: A Review
- Effects of lithium on serum Brain-Derived Neurotrophic Factor in Alzheimer's patients with agitation
- The controversy around anti-amyloid antibodies for treating Alzheimer's disease : The European Medical Agency's ruling against the latest anti-amyloid drugs highlights the ongoing debate about their safety and efficacy